News2020-05-23T14:50:18+00:00

Read Our Recent News

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals

London, October 27th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier of Tungsten-188/ Rhenium-188 generators for the production of high-energy beta emitting Rhenium-188, as well as a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers. These Heads of Terms will precede a Strategic Alliance and Supply Agreement for developing Rhenium-188 API solutions, which are suitable for [...]

October 27th, 2020|

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.

London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer. Professor Gary Cook, Professor of PET Imaging at King’s College London said, “We have scanned our first participant; the images I reviewed are of excellent quality and clearly show the heterogeneity of PD-L1 expression [...]

October 9th, 2020|

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The study will be carried out [...]

September 10th, 2020|

NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS).

NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS). London, June 5th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, is pleased to announce that it is participating as an Industrial Partner in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS). The Programme, led by Phil Blower (Professor of Imaging Chemistry at King’s College, London) has been awarded £6 million from the [...]

June 15th, 2020|

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product.

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product. Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020.   London, May 20th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced a collaboration with University Hospital Aachen to initiate a cancer therapy programme to bring a novel radiopharmaceutical product to patients with HER2 positive breast cancer. The programme will [...]

May 20th, 2020|

NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for European clinical trial programme

NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for  European clinical trial programme Precision oncology therapeutics company moves centre of operations from China London, April 28, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, today announced a number of key management changes. The company has also established a UK subsidiary office and moved its centre of operations as it prepares to start clinical trials for [...]

April 28th, 2020|

Contact Us With Any Questions

Please do not hesitate to get in touch with any questions.

CONTACT US